Retractable Technologies, Inc. RVP PHARMA
Company Overview
Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. The company offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. It distributes its products through general line and specialty distributor; international distributors; and national direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $38.27M (+15.8% YoY); net profit $-12.57M.
- Trailing 12 Months Year-on-year growth — revenue -31.1%.
- 5-Year Trend Long-term compounding — revenue CAGR -0.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -0.12% |
| 1 Year: | -31.10% |
Stock Price Performance
| 1 Year: | -12.50% |
| 6 Months: | +6.06% |
| 3 Months: | +1.45% |
| 1 Month: | +4.48% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.47 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Revenue declined at -0.1% CAGR over 5 years.
- Trading 34.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RVP Retractable Technologies, Inc. PHARMA | 0.70 | -5.83 | $20.96M | 0.00% | -10.73% | -4.51% | -0.12% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 6.92M | 7.65M | 10.41M | 7.67M | 7.47M | 9.86M | 8.26M | 7.93M | 9.60M | 11.64M | 12.63M | 11.20M | 11.57M | 27.09M | 50.07M | 42.50M | 36.36M | 44.74M | 14.34M | 23.06M | 11.00M | 7.97M | 10.34M | 7.60M | 6.03M | 10.35M | 8.30M | 10.45M | 10.09M | 9.44M | 7.18M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.30M | 10.55M | 8.40M | 10.97M | 8.02M |
| Gross Profit | 1.72M | 2.18M | 3.85M | 2.40M | 2.60M | 3.22M | 2.19M | 2.62M | 3.26M | 2.32M | 2.21M | 3.26M | 2.86M | 2.07M | 2.80M | 2.50M | 2.49M | 2.93M | 3.77M | 4.95M | 3.53M | 3.67M | 13.83M | 27.99M | 19.64M | 13.39M | 15.57M | 3.65M | 4.74M | 2.87M | 376.91K | 4.32M | 1.90M | -419.92K | -14.81K | -1.91K | -107.09K | 1.69M | -1.53M | -838.41K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.19M | 3.55M | 5.34M | -722.19K | 3.85M |
| Operating Income | -1.99M | -1.34M | 420.89K | -895.10K | -1.24M | -199.38K | -894.17K | -605.54K | -81.44K | -1.15M | -1.31M | -32.86K | -156.97K | -938.68K | -60.23K | - | -174.78K | 328.80K | 978.42K | - | 480.71K | 959.88K | 10.35M | 23.42M | 12.67M | 7.97M | 9.73M | -2.06M | -690.62K | -2.74M | -5.03M | -935.87K | -2.99M | -5.76M | -5.14M | -3.19M | -3.66M | -3.65M | -807.67K | -4.69M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.31M | 1.81M | 2.26M | -180.17K | -2.30M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.45K | 22.26K | 20.59K | 21.61K | 20.44K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -10.21M | -85.66K | 372.74K | -2.35M | -4.22M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 285.76K | 1.81K | 1.69K | 2.02K | 1.84K |
| Net Income | -2.04M | -1.39M | 371.43K | -944.35K | 6.44M | -254.83K | -939.09K | -656.69K | -125.30K | -1.19M | -1.35M | -66.63K | -179.00K | -948.00K | -63.00K | -150.00K | -129.22K | 391.75K | 1.02M | 1.86M | 322.77K | 3.77M | 8.63M | 17.96M | 10.66M | 6.52M | 7.62M | -3.64M | 5.39M | 990.97K | -3.87M | -4.06M | 429.38K | -14.16M | -1.92M | -10.50M | -87.47K | 371.05K | -2.35M | -4.23M |
| Diluted EPS | -0.08 | -0.06 | 0.00 | -0.04 | 0.21 | -0.02 | -0.04 | -0.03 | -0.01 | -0.04 | -0.05 | -0.01 | -0.01 | -0.03 | -0.01 | -0.01 | -0.01 | 0.01 | 0.03 | 0.05 | 0.00 | 0.11 | 0.33 | 0.52 | 0.31 | 0.19 | 0.23 | -0.11 | 0.16 | 0.03 | -0.13 | -0.14 | 0.01 | -0.48 | -0.07 | -0.35 | 0.00 | 0.01 | - | -0.14 |
| R&D Expense | 184.72K | 192.24K | 129.19K | 116.31K | 167.68K | 125.78K | 124.92K | 146.85K | 117.94K | 148.45K | 157.40K | 159.92K | 144.23K | 141.47K | 146.49K | - | 127.46K | 115.51K | 134.92K | - | 138.54K | 126.25K | 134.57K | 149.28K | 399.04K | 199.20K | 95.54K | 206.39K | 105.75K | 129.76K | 138.76K | 150.96K | 142.26K | 199.09K | 174.69K | 191.19K | 160.05K | 199.46K | - | 170.42K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38.98M | 36.22M | 32.10M | 33.64M | 30.79M | 34.52M | 29.55M | 29.83M | 34.49M | 33.27M | 41.80M | 81.86M | - | 94.82M | 43.60M | 33.05M | 38.27M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 66.57M | 34.49M | 34.08M | 38.22M |
| Gross Profit | 13.52M | 12.52M | 10.90M | 11.18M | 10.31M | 12.02M | 10.57M | 10.34M | 9.97M | 10.22M | 14.14M | 37.01M | - | 28.25M | 9.11M | -1.03M | 47.05K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 25.27M | 14.37M | 14.18M | 14.32M |
| Operating Income | -13.30M | -6.66M | -4.09M | -3.94M | -5.93M | -2.16M | -3.21M | -3.51M | -3.78M | -1.33M | 2.97M | 24.07M | - | 2.98M | -5.26M | -15.20M | -14.27M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.94M | -1.24M | 4.17M | -4.42M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 170.65K | 152.17K | 122.50K | 87.90K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.16M | -8.92M | -3.52M | -12.27M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 83.87K | -1.91M | 8.37M | 291.29K |
| Net Income | -9.42M | 2.40M | 1.42M | -4.13M | -6.21M | -2.35M | 4.31M | -3.69M | -3.74M | -1.34M | 3.15M | 24.22M | - | 5.08M | -7.01M | -11.89M | -12.57M |
| Diluted EPS | -0.45 | 0.04 | 0.02 | -0.19 | -0.26 | -0.12 | 0.20 | -0.15 | -0.14 | -0.06 | 0.07 | 0.80 | - | 0.15 | -0.24 | -0.40 | -0.43 |
| R&D Expense | 1.03M | 885.45K | 815.02K | 871.85K | 837.07K | 616.78K | 607.53K | 571.84K | 740.57K | 621.37K | 516.10K | 574.53K | 901.38K | 525.73K | 581.17K | 673.94K | 675.57K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 53.19M | 48.92M | 47.63M | 49.10M | 45.35M | 42.29M | 38.78M | 38.16M | 36.96M | 39.18M | 104.97M | - | 195.67M | 179.67M | 160.72M | 142.63M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 88.81M | 77.65M | 73.27M | 63.08M |
| Cash & Equivalents | 33.28M | 18.13M | 23.27M | 25.67M | 25.96M | 22.13M | 18.05M | 18.05M | 16.20M | 14.88M | 9.65M | 5.93M | 17.57M | - | 19.72M | 12.67M | 4.24M | 2.59M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.68M | 17.58M | 19.19M | 17.19M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.84M | 10.67M | 7.79M | 7.90M |
| Total Liabilities | - | - | 14.29M | 10.27M | 11.90M | 20.20M | 18.52M | 11.51M | 10.67M | 10.98M | 11.34M | 10.64M | 55.09M | - | 89.13M | 80.38M | 73.55M | 68.26M |
| Current Liabilities | - | - | 9.99M | 6.13M | 8.08M | 16.62M | 15.10M | 8.10M | 7.17M | 7.90M | 8.62M | 8.26M | 27.90M | - | 12.14M | 9.38M | 8.78M | 9.60M |
| Long Term Debt | - | - | 4.30M | 4.14M | 3.83M | 3.58M | 3.43M | 3.42M | 3.50M | 3.08M | 2.64M | 2.38M | 2.71M | - | 1.53M | 1.23M | 900.04K | 530.37K |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.82M | 1.54M | 1.23M | 895.64K |
| Total Equity | 42.21M | 35.92M | 38.90M | 38.65M | 35.73M | 28.65M | 26.58M | 30.78M | 28.11M | 27.17M | 25.61M | 28.54M | 49.88M | - | 106.54M | 99.29M | 87.17M | 74.38M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.02M | 34.02M | 34.02M | 34.02M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - | -3.25M | -794.91K | -2.92M | -1.20M | 2.19M | 19.00M | - | 16.77M | 2.77M | -11.56M | -7.06M |
| Investing Cash Flow | - | - | - | - | - | - | -864.11K | -1.95M | -91.88K | -3.37M | -5.28M | -19.33M | - | -31.20M | -10.76M | 3.66M | 5.98M |
| Financing Cash Flow | - | - | - | - | - | - | 32.34K | 896.08K | 1.69M | -666.80K | -626.84K | 11.96M | - | 4.99M | 941.64K | -535.43K | -567.32K |
| Capital Expenditure | -2.38M | -169.41K | -826.09K | -510.12K | -283.29K | -1.01M | -1.47M | -1.95M | -91.88K | -382.16K | -632.08K | -21.05M | - | -16.83M | -852.98K | -1.44M | -535.64K |
| Free Cash Flow | - | - | - | - | - | - | -4.72M | -2.74M | -3.01M | -1.58M | 1.56M | -2.05M | - | -61.95K | 1.91M | -13.00M | -7.60M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | -9.44M | -7.05M | -8.43M | -1.65M |
| Share Buybacks | - | - | - | 122.20K | 974.41K | - | - | - | - | - | - | - | 5.27M | 7.62M | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 34.7% | 34.6% | 34.0% | 33.2% | 33.5% | 34.8% | 35.8% | 34.7% | 28.9% | 30.7% | 33.8% | 45.2% | - | 29.8% | 20.9% | -3.1% | 0.1% |
| Operating Margin % | -34.1% | -18.4% | -12.7% | -11.7% | -19.3% | -6.3% | -10.9% | -11.8% | -11.0% | -4.0% | 7.1% | 29.4% | - | 3.1% | -12.1% | -46.0% | -37.3% |
| Net Margin % | -24.2% | 6.6% | 4.4% | -12.3% | -20.2% | -6.8% | 14.6% | -12.4% | -10.8% | -4.0% | 7.5% | 29.6% | - | 5.4% | -16.1% | -36.0% | -32.8% |
| ROE % | -26.2% | 6.2% | 3.7% | -11.6% | -21.7% | -8.9% | 14.0% | -13.1% | -13.7% | -5.2% | 11.0% | 48.6% | - | 4.8% | -7.1% | -13.6% | -16.9% |
| ROCE % | - | -15.4% | -9.6% | -10.0% | -18.3% | -7.1% | -9.4% | -11.1% | -12.5% | -4.7% | 9.6% | 31.2% | - | 1.6% | -3.1% | -10.0% | -10.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 1.94% | 581.74K | $418.44K |
| 2 | Eversept Partners, LP | 1.94% | 580.92K | $417.86K |
| 3 | Renaissance Technologies, LLC | 1.47% | 441.41K | $317.50K |
| 4 | Blackrock Inc. | 0.81% | 241.12K | $173.44K |
| 5 | Geode Capital Management, LLC | 0.40% | 121.00K | $87.04K |
| 6 | Bridgeway Capital Management, LLC | 0.30% | 88.54K | $63.69K |
| 7 | Citadel Advisors Llc | 0.29% | 87.33K | $62.82K |
| 8 | Vanguard Fiduciary Trust Co | 0.28% | 85.26K | $61.33K |
| 9 | Susquehanna International Group, LLP | 0.26% | 78.86K | $56.72K |
| 10 | State Street Corporation | 0.20% | 59.80K | $43.01K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RVP
RVP Stock Gains Post Q2 Earnings Despite Fall in Sales & Unit Volumes - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOQWRWMU1EZXE4NXlBZFR2blQ1N0tya3gyMm81MkgzbHRKRm8yM2pwbnBrNHI0LTlhMGtvLXFJX25sUUIxSVFCRkt4VUpWdS1mdTVNQnRmc1hzSXoxUnZZMVBRT2hBYVpvR19rRFBVM052T2JiWnJxT3RTODhZZC1lR1FpY0pQMFd0SFFERl…
A proposed bill would offer tax breaks to make more medical supplies in the U.S. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPX3R3a3EyVnJ3ZXlsUXA0X2hzeWxqdHdNS25LM0lwaXJsYWs3R1NuV0VDNFFUNFp5NUxfdVVPNVpkYTc4QnFDZjlCVHNlZ1Z1WUpkWW9mWXJOLTluRVk3NDhMV1h4UlJ4TmcwY3c3TXVEZWYwaU92SENlakNWTzIzblZMRURJWGFIMUFaaG…
RVP - Finviz
<a href="https://news.google.com/rss/articles/CBMiREFVX3lxTFBoOVhmNFpUai1SUkpjUXJxWFBtZDhZUWZvc0ZxWHZZVWkyckJCUFpJSTlRMWRUczhXcG11WFFEVEU4UGU1?oc=5" target="_blank">RVP</a> <font color="#6f6f6f">Finviz</font>…
(AMEX: RVP) Share Price, RVP Stock News, RVP Share Price & Updates - kalkine.ca
<a href="https://news.google.com/rss/articles/CBMiTEFVX3lxTE13c1NEcWZCaF9feVl3WmVGZEo1V2Q4Y3pxdThzcW5oS2dXdVNyaXIxakNfVUtFM0NhZW5RaHNHSU9aZW9JZXhfb01GTjQ?oc=5" target="_blank">(AMEX: RVP) Share Price, RVP Stock News, RVP Share Price & Updat…
Retractable Technologies Reports $6.4M Equity-Sale Gain in Q2 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNdDlSNVB0ZVpfdVVYdWZkVDFmZTJ3d0lZRkQxZXBDZDk5dmdoSEo0eEtNWjN0d1BzVGtESTNrVngyNkxpa0F5anI5TUhQckFXeTlVWXQyTlhaTUtyaW5TbVQzWWVubko1bDZvWHltTjR2eFpIUEF1a1ZnNWtvOWhrZ2taZGpqTzNVcVBHY0…
Retractable Stock Slips Post Q1 Earnings, Sales Decline Y/Y - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxQaTk2ZTVfSjgzM0E5UjhPMUFjLWxHbl9CUlRocUhyZGJIN0NMd0pKenFlOWxkVlB5bWVKdzE2VUxCUFJGWDlhNEJBY2VEaWx0X28yOWE3SVg1RjBYYjNsRjkxVGlEQ3loSDhFZzZIcGhKSnpQbDBtZjZzc3poSDhraGtTWEVfUWdjQ096Wm…
RVP — Frequently Asked Questions
What is the current share price of Retractable Technologies, Inc. (RVP)?
As of 2026-09-19 21:16 PDT, Retractable Technologies, Inc. (RVP) trades at $0.70 on NYSE American. Its 52-week range is $0.62 to $1.06.
What is the market capitalisation of RVP?
Retractable Technologies, Inc. (RVP) has a market capitalisation of $20.96M on NYSE American.
What is the P/E ratio of RVP?
RVP trades at a trailing price-to-earnings (P/E) ratio of -5.83. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.30.
What is the return on equity (ROE) of RVP?
RVP has a return on equity (ROE) of -4.51%. Its return on capital employed (ROCE) is -10.73%.
Is RVP a good stock to buy?
This page provides a data-driven analysis of Retractable Technologies, Inc. (RVP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.